Avrobio Touts New Positive Data From Gaucher Disease Gene Therapy

  • AVROBIO Inc AVRO announced new interim data from AVR-RD-02, an investigational gene therapy for Gaucher disease.
  • The data showed stabilization or reversal of multiple clinically relevant measures in five patients with Gaucher disease after receiving a single dose of AVR-RD-02.
  • An 11-year-old patient was dosed. Fifteen months post gene therapy, the patient has normalized peripheral glucocerebrosidase (GCase) enzyme activity and plasma chitotriosidase, a marker of activated macrophages, and remains off enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).
  • Related: Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study.
  • The patient's albumin levels increased by 33% eight months post-gene therapy, reflecting improvements in lymphadenopathy and enteropathy​. 
  • ​Additionally, the patient did not develop any new lesions post-gene therapy.
  • All four adult GD1 patients in the Guard1 trial saw sustained engraftment with vector copy numbers (VCN) between 0.54 - 0.86 per diploid genome 14 weeks to two years post-gene therapy. Reconstitution of GCase enzyme activity in plasma and peripheral blood leukocytes within the normal range.
  • Notably, three of the four dosed patients demonstrate a reduced liver and spleen volume below their ERT baseline. 
  • AVROBIO plans to initiate a global, registrational Phase 2/3 trial in Gaucher disease type 3 (GD3) in 2H of 2023.
  • Price Action: AVRO shares are down 0.90% at $0.83 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!